Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1081-1100 of 2,251 trials

DAY101 for Pediatric Brain Cancer and Solid Tumors

We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.

Malignant Glioma>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

External Cephalic Version: Propofol vs. Spinal Analgesia

We are comparing the use of Propofol and spinal analgesia for sedation during a procedure to turn breech babies. Our goal is to find out which method has a higher success rate and fewer complications.

External Cephalic Version>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Prostate Cancer: Personalized Radiotherapy and Hormone Therapy

We are studying whether using AI to customize radiotherapy and hormone treatment can help prostate cancer patients while reducing the overall treatment time. This trial is for those with high-risk localized prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Soft Tissue Sarcomas: Atezolizumab with Radiotherapy

We are studying whether adding an immunotherapy drug to radiotherapy helps patients with localized soft tissue sarcomas achieve better treatment outcomes. The trial will also look at the safety and immune response to this combination.

Localized Soft Tissue Sarcoma3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

VEXAS Syndrome: Azacitidine Treatment Study

We are studying whether Azacitidine can help reduce symptoms and improve health in patients with VEXAS Syndrome. The trial will also assess the safety of this treatment and its impact on patients' quality of life.

VEXAS Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyRheumatology

Membranous Nephropathy: Personalized Rituximab Treatment Study

We are exploring whether an AI-driven personalized treatment plan for membranous nephropathy is more effective than standard rituximab treatment. This study aims to improve patient outcomes and remission rates.

Acute GlomerulonephritisMembranous Nephropathy6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNephrology

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Axial Spondyloarthritis and Psoriatic Arthritis: Ixekizumab Study

We are examining how ixekizumab affects inflammation in patients with axial spondyloarthritis and psoriatic arthritis. This study uses whole-body MRI to measure changes in joints and entheses.

Psoriatic ArthritisAxial Spondyloarthritis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology

Stroke Treatment: Anesthesia vs. Sedation

We are comparing general anesthesia to sedation with high-flow nasal cannula for patients undergoing treatment for acute ischemic stroke. Our goal is to see which method leads to better recovery and fewer complications.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

Whipple's Procedure: Antibiotic Treatment Comparison

We are studying whether pre-emptive antibiotics can lower the risk of infections after Whipple's surgery compared to standard antibiotic treatment. This trial aims to improve recovery outcomes for patients undergoing this procedure.

Pancreatoduodenectomy with High Risk for Contaminated Bile>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Colorectal Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons detect brain metastases from colorectal cancer during surgery. This study aims to see how well it works and its safety for patients.

Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncology

Rectal Cancer Surgery: SGM-101 Imaging Study

We are testing a new imaging agent, SGM-101, to see if it helps surgeons better detect rectal cancer during surgery. This study is for patients with locally advanced or recurrent rectal cancer who are undergoing curative surgery.

Rectal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Rectal Polyps: SGM-101 Fluorescent Tracer Study

We are investigating a new imaging technique using SGM-101 to help identify cancerous and non-cancerous tissues in patients with rectal polyps. This study aims to improve how doctors detect early-stage rectal cancer.

Early Rectal Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Locally Advanced Rectal Cancer: Dostarlimab and Radiotherapy

We are studying a new treatment combining dostarlimab and short-course radiotherapy for patients with specific types of rectal cancer. The goal is to see if this approach helps improve treatment success and quality of life.

Locally Advanced Rectal Cancer with Genetic Deficiencies>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Metastatic Non-Small-Cell Lung Cancer: LN-145 Treatment Study

We are investigating whether LN-145, a type of immune cell therapy, is safe and effective for patients with metastatic non-small-cell lung cancer. The study will assess how well it works in shrinking tumors and improving patient outcomes.

Metastatic Non-Small-Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hyperbaric Oxygen Therapy for Sudden Hearing Loss

We are studying whether adding hyperbaric oxygen treatment to standard care improves hearing in people with sudden sensorineural hearing loss. The trial will also look at quality of life and safety of this treatment approach.

Sudden Hearing Loss3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOtolaryngology

Vitamin D3 Doses in Critically Ill Patients on Kidney Support

We are comparing two doses of vitamin D3 to see how they affect vitamin levels and health outcomes in ICU patients receiving kidney support. This study may help improve treatment for those with severe vitamin D deficiency.

Vitamin D DeficiencyMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyNephrology

Post-Stroke Spasticity: Dry Needling vs. Botulinum Toxin

We are exploring how Dry Needling and Botulinum Toxin type A affect spasticity in the lower limbs of stroke survivors. The study will also look at safety, muscle function, and quality of life.

Spasticity after Stroke3-6 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology